Caterpillar Drug Formulary Update -- Effective May 1, 2025

Active Employees and certain Retirees that are covered by the prescription drug benefit provisions of the Caterpillar Inc. Employee Health, Life and Disability Benefit Program, the Caterpillar Inc. Retiree Benefit Program, the Caterpillar Inc. Group Insurance Plan A, and the Caterpillar Inc. Group Insurance Plan B.

| available at ben Additic | ons to Caterpillar Dr | ug Formulary Effective May 1 | , 2025 | |
|-----------------------------|--------------------------------|---------------------------------|--|--|
| Drug Name | | Drug Name | | |
| TRYNGOLZA | T4 PA QL | ATTRUBY | T4 PA QL | |
| CTEXLI | T4 PA QL | QINLOCK | T4 PA QL | |
| FASENRA | T4 PA QL | | | |
| | | | | |
| | to Caterpillar Specia | alty Products List Effective Ma | ay 1, 2025 | |
| Drug Name | TO DA OD | Drug Name | | |
| OPFOLDA | T3 PA SP | | | |
| | Recent New Gener | ics Announced May 1, 2025 | | |
| Brand Name | | Generic Name + | | |
| CYMBALTA | Т3 | duloxetine 40 mg | T1 | |
| PURIXAN | T4 PA | mercaptopurine susp | T3 PA | |
| XARELTO | T2 | rivaroxaban | T2 | |
| VIIBRYD | T3 ST | vilazodone | T1 ST | |
| BRILINTA | Т3 | ticagrelor | T1 | |
| SANDOSTATIN LAR | T4 PA SP | octreotide acetate er | T4 PA SP | |
| TASIGNA | T4 PA SP | nilotinib hcl | T4 PA SP | |
| THIOLA | T4 | VENXXIVA | T4 | |
| | | Prug Formulary Effective May | | |
| Drug Name | igeo to outerpinar b | Drug Name | 1, 2020 | |
| fenofibrate 120mg | ТЗ | ZONEGRAN | T4 QL | |
| clomipramine | T1 | rufinamide | T1 | |
| PURIXAN | T4 PA | | T4 | |
| | | METHITEST | | |
| PHENYTEK | T1 | methyltestosterone 10mg cap | T4 | |
| MYSOLINE | T4 | ANDROGEL | T4 | |
| | T4 | TESTIM 1% (50MG) GEL | T4 | |
| EQUETRO | T4 | testosterone 1.62% gel pump | T1 | |
| carbamazepine susp | T2 | DEPO-TESTOSTERONE | T1 | |
| FELBATOL | T4 | TRILEPTAL SUSP | T4 | |
| ZONISADE SUSP | T4 PA | CHENODAL | T4 PA QL | |
| | ges to Caterpillar Dr | ug Formulary Effective Augu | st 1, 2025 | |
| Drug Name | | Drug Name | | |
| TROKENDI XR | T4 ST | | | |
| TRILEPTAL TABS | T4 | | | |
| BANZEL | T4 | | | |
| VIMPAT | T4 | | | |
| BRIVIACT | T4 PA | | | |
| FYCOMPA | T4 PA | | | |
| | ons to Caterpillar Dro | ug Formulary Effective May 1 | , 2025 | |
| Deletions | | Alternative(s) | | |
| GABITIRL due to manufacture | | | 4 2025 | |
| | s to Caterpillar Drug | g Formulary Effective August | 1, 2025 | |
| Deletions STELARA | | Alternative(s) | Alternative(S) Biosimilar (ustekinumab) to be announced | |
| | | | | |
| | able in all strengths or dosag | a farma | | |

health needs and whether any of the alternative treatments is right for you. In the event that the content of this document or any representations made by any person regarding the plan conflict with or are inconsistent with the provisions of the plan document, the provisions of the plan document are controlling. To the fullest extent permitted by law, Caterpillar reserves the right to amend, modify, suspend, replace or terminate any of its plans, policies or programs, in whole or in part, at any time and for any reason, by appropriate company action.